Assetmark Inc. grew its stake in Sanofi SA (NYSE:SNY) by 1.1% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 183,285 shares of the company’s stock after purchasing an additional 1,988 shares during the quarter. Assetmark Inc.’s holdings in Sanofi were worth $8,187,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its holdings in Sanofi by 342.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 147,330 shares of the company’s stock valued at $6,581,000 after purchasing an additional 114,008 shares during the last quarter. Wallace Capital Management Inc. boosted its holdings in Sanofi by 0.9% in the 3rd quarter. Wallace Capital Management Inc. now owns 183,264 shares of the company’s stock valued at $8,186,000 after purchasing an additional 1,619 shares during the last quarter. Clarius Group LLC acquired a new position in Sanofi in the 3rd quarter valued at about $212,000. Holderness Investments Co. acquired a new position in Sanofi in the 3rd quarter valued at about $204,000. Finally, GFS Advisors LLC boosted its holdings in Sanofi by 6.2% in the 3rd quarter. GFS Advisors LLC now owns 87,675 shares of the company’s stock valued at $3,916,000 after purchasing an additional 5,080 shares during the last quarter. Institutional investors and hedge funds own 7.06% of the company’s stock.
Several equities analysts have weighed in on SNY shares. Argus boosted their target price on shares of Sanofi from $46.00 to $48.00 and gave the company a “buy” rating in a report on Friday, August 24th. Citigroup raised shares of Sanofi from a “neutral” rating to a “buy” rating in a research note on Friday, August 10th. Bank of America raised shares of Sanofi from a “neutral” rating to a “buy” rating and set a $55.00 price target on the stock in a research note on Monday, September 10th. Barclays raised shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Thursday, November 1st. Finally, Zacks Investment Research raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Tuesday, August 28th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $49.50.
Sanofi (NYSE:SNY) last released its quarterly earnings results on Wednesday, October 31st. The company reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.09. The business had revenue of $9.39 billion for the quarter, compared to the consensus estimate of $9.10 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The business’s revenue was up 1.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.71 EPS. On average, research analysts forecast that Sanofi SA will post 3.09 EPS for the current year.
TRADEMARK VIOLATION WARNING: This article was first reported by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://baseballnewssource.com/2018/12/08/sanofi-sa-sny-shares-bought-by-assetmark-inc/3063877.html.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: Return on Investment (ROI) Defined, Explained
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.